A Call for Randomized Controlled Trials of Antiretroviral Therapy for HIV-2 Infection in West Africa

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2008 Oct 4

PMID 18832869

Citations 39

Authors

Geoffrey S Gottlieb

Serge-Paul Eholie

John N Nkengasong

Sabelle Jallow

Sarah Rowland-Jones

Hilton C Whittle

Papa Salif Sow

Affiliations

Soon will be listed here.

Citing Articles

The HIV-2 proviral landscape is dominated by defective proviruses.

Koofhethile C, Gao C, Chang C, Lian X, Shapiro R, Yu X AIDS. 2023; 38(3):309-316.

PMID: 37916471 PMC: 10842655. DOI: 10.1097/QAD.0000000000003776.

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis.

Ngoufack Jagni Semengue E, Santoro M, Ndze V, Kae A, Yagai B, Nka A PLOS Glob Public Health. 2023; 2(10):e0000826.

PMID: 36962573 PMC: 10021461. DOI: 10.1371/journal.pgph.0000826.

Future of HIV2 and HIV2 + 1 Infected Patients Treated with Antiretrovirals Followed at the Day Hospital HIV Care Unit from 2011 to 2015.

Diallo I, Ouedraogo S, Sawadogo A, Ouedraogo G, Diendere E, Zoungrana J J Int Assoc Provid AIDS Care. 2022; 21:23259582221143675.

PMID: 36474417 PMC: 9732798. DOI: 10.1177/23259582221143675.

Evasion of cGAS and TRIM5 defines pandemic HIV.

Zuliani-Alvarez L, Govasli M, Rasaiyaah J, Monit C, Perry S, Sumner R Nat Microbiol. 2022; 7(11):1762-1776.

PMID: 36289397 PMC: 9613477. DOI: 10.1038/s41564-022-01247-0.

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.

Tchounga B, Charpentier C, Coffie P, Dabis F, Descamps D, Eholie S PLoS One. 2020; 15(8):e0236642.

PMID: 32756581 PMC: 7406077. DOI: 10.1371/journal.pone.0236642.

References

Andreasson P, Dias F, Naucler A, Andersson S, Biberfeld G . A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS. 1993; 7(7):989-93. View

De Cock K, Odehouri K, Colebunders R, Adjorlolo G, Lafontaine M, Porter A . A comparison of HIV-1 and HIV-2 infections in hospitalized patients in Abidjan, Côte d'Ivoire. AIDS. 1990; 4(5):443-8. DOI: 10.1097/00002030-199005000-00010. View

Simon F, Matheron S, Tamalet C, Bartczak S, PEPIN J, Dhiver C . Cellular and plasma viral load in patients infected with HIV-2. AIDS. 1993; 7(11):1411-7. DOI: 10.1097/00002030-199311000-00002. View

Kanki P, Travers K, Mboup S, Hsieh C, Marlink R, Gueye-Ndiaye A . Slower heterosexual spread of HIV-2 than HIV-1. Lancet. 1994; 343(8903):943-6. DOI: 10.1016/s0140-6736(94)90065-5. View

Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T . Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994; 265(5178):1587-90. DOI: 10.1126/science.7915856. View

Markowitz M, Saag M, Powderly W, Hurley A, Hsu A, Valdes J . A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995; 333(23):1534-9. DOI: 10.1056/NEJM199512073332204. View

Collier A, Coombs R, Schoenfeld D, Bassett R, Timpone J, Baruch A . Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996; 334(16):1011-7. DOI: 10.1056/NEJM199604183341602. View

CARPENTER C, Fischl M, Hammer S, Hirsch M, Jacobsen D, Katzenstein D . Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997; 277(24):1962-9. View

Clark N, Dieng Sarr A, Sankale J, Kanki P, Kazanjian P, Winfield R . Immunologic and virologic response of HIV-2 infection to antiretroviral therapy. AIDS. 1999; 12(18):2506-7. View

10.

Popper S, Sarr A, Travers K, Gueye-Ndiaye A, Mboup S, Essex M . Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis. 1999; 180(4):1116-21. DOI: 10.1086/315010. View

11.

Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S . Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol. 2005; 43(1):484-7. PMC: 540186. DOI: 10.1128/JCM.43.1.484-487.2005. View

12.

Willey S, Peters P, Sullivan W, Dorr P, Perros M, Clapham P . Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antiviral Res. 2005; 68(2):96-108. DOI: 10.1016/j.antiviral.2005.07.006. View

13.

Rodes B, Toro C, Sheldon J, Jimenez V, Mansinho K, Soriano V . High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS. 2005; 20(1):127-9. DOI: 10.1097/01.aids.0000196171.35056.6c. View

14.

Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G . CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS. 2006; 20(3):459-62. DOI: 10.1097/01.aids.0000199829.57112.2f. View

15.

Ndour C, Batista G, Manga N, Ngom Gueye N, Dia Badiane N, Fortez L . [Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: preliminary study]. Med Mal Infect. 2006; 36(2):111-4. DOI: 10.1016/j.medmal.2005.11.012. View

16.

Rodes B, Sheldon J, Toro C, Jimenez V, Angel Alvarez M, Soriano V . Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother. 2006; 57(4):709-13. DOI: 10.1093/jac/dkl034. View

17.

Gottlieb G, Hawes S, Agne H, Stern J, Critchlow C, Kiviat N . Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS. 2006; 20(6):895-900. PMC: 3726185. DOI: 10.1097/01.aids.0000218554.59531.80. View

18.

Boyer P, Sarafianos S, Clark P, Arnold E, Hughes S . Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?. PLoS Pathog. 2006; 2(2):e10. PMC: 1364504. DOI: 10.1371/journal.ppat.0020010. View

19.

Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S . Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS. 2006; 20(10):1455-8. DOI: 10.1097/01.aids.0000233582.64467.8e. View

20.

Schim van der Loeff M, Awasana A, Sarge-Njie R, van der Sande M, Jaye A, Sabally S . Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol. 2006; 35(5):1322-8. DOI: 10.1093/ije/dyl037. View